NCT03960957 - Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines | Biotech Hunter

Enrollment

301

Participants

Timeline

Start Date

June 17, 2019

Primary Completion Date

September 27, 2019

Study Completion Date

April 16, 2020

Conditions

Glabellar Frown Lines

Interventions

BIOLOGICAL

AbobotulinumtoxinA

Treatment of glabellar facial lines with 50 U AbobotulinumtoxinA

OTHER

Placebo

Treatment of glabellar facial lines with placebo

Trial Locations (11)

Galderma Study Site, Washington D.C.

Galderma Study Site, Atlanta

Galderma Study Site, Coral Gables

Galderma Study Site, Cincinnati

Galderma Study Site, St Louis

Galderma Study Site, Omaha

Galderma Study Site, Spring

Galderma Study Site, Austin

Galderma Study Site, Redondo Beach

Galderma Study Site, San Diego

Galderma Study Site, Westport